Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

VERA

+ Watchlist+ Portfolio

Vera Therapeutics, Inc.

Regulated industryDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$26.20
52-Week Range
$25.34 – $56.05
Market Cap
$1.85B
P/E (TTM)
—
EPS (TTM)
-5.90
Dividend Yield
0.00%
Advanced Metrics
Price/Book
5.55
PEG Ratio
—
Return on Equity
-113.46%
Return on Assets
-54.35%
Gross Margin
67.93%
Operating Margin
-4160.07%
Profit Margin
0.00%
Current Ratio
7.91
Debt/Equity
0.23
Total Debt
$76.79M
Free Cash Flow
$-244.62M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$1.54B

Market Snapshot

About

Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. The company is advancing atacicept, a novel fusion protein, for IgA nephropathy and other autoimmune conditions. Vera aims to address unmet medical needs in complement-mediated and autoimmune disorders.